glp-1 obesity drug news updates Alarming rise in weight loss overdoses How Supply and Demand for
Description
The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status
others seek natural alternatives to the prescriptions
Could addiction be next?

And for those exploring GLP-1s for weight loss, it's a much more sustainable way to manage weight (low and slow is the way to go)

The aim of the present review is to examine the cellular processes underlying the actions of these new, highly significant classes of peptide receptor agonists

Our results reveal the existence of residue networks crucial for unimolecular agonist-mediated receptor activation and their distinct signaling patterns, which might be useful to the rational design of biased drug leads.
